AU2022362855B2 - Inhibitors of human immunodeficiency virus replication - Google Patents

Inhibitors of human immunodeficiency virus replication

Info

Publication number
AU2022362855B2
AU2022362855B2 AU2022362855A AU2022362855A AU2022362855B2 AU 2022362855 B2 AU2022362855 B2 AU 2022362855B2 AU 2022362855 A AU2022362855 A AU 2022362855A AU 2022362855 A AU2022362855 A AU 2022362855A AU 2022362855 B2 AU2022362855 B2 AU 2022362855B2
Authority
AU
Australia
Prior art keywords
formulation
rat
administration
formula
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2022362855A
Other languages
English (en)
Other versions
AU2022362855A1 (en
Inventor
Gautam Dalwadi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ViiV Healthcare UK No 5 Ltd
Original Assignee
ViiV Healthcare UK No 5 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ViiV Healthcare UK No 5 Ltd filed Critical ViiV Healthcare UK No 5 Ltd
Publication of AU2022362855A1 publication Critical patent/AU2022362855A1/en
Application granted granted Critical
Publication of AU2022362855B2 publication Critical patent/AU2022362855B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2022362855A 2021-10-13 2022-10-12 Inhibitors of human immunodeficiency virus replication Active AU2022362855B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163255056P 2021-10-13 2021-10-13
US63/255,056 2021-10-13
US202163257212P 2021-10-19 2021-10-19
US63/257,212 2021-10-19
PCT/IB2022/059780 WO2023062559A1 (en) 2021-10-13 2022-10-12 Inhibitors of human immunodeficiency virus replication

Publications (2)

Publication Number Publication Date
AU2022362855A1 AU2022362855A1 (en) 2024-05-02
AU2022362855B2 true AU2022362855B2 (en) 2025-08-14

Family

ID=84044276

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022362855A Active AU2022362855B2 (en) 2021-10-13 2022-10-12 Inhibitors of human immunodeficiency virus replication

Country Status (10)

Country Link
US (1) US20240423985A1 (https=)
EP (1) EP4415685A1 (https=)
JP (1) JP2024535596A (https=)
KR (1) KR20240074850A (https=)
AU (1) AU2022362855B2 (https=)
CA (1) CA3234219A1 (https=)
CL (1) CL2024001073A1 (https=)
IL (1) IL311982A (https=)
MX (1) MX2024004551A (https=)
WO (1) WO2023062559A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202128648A (zh) * 2019-10-04 2021-08-01 英商Ｖｉｉｖ醫療保健英國(Ｎｏ 5)有限公司 人類免疫不全病毒複製之抑制劑
US12594276B2 (en) 2024-02-05 2026-04-07 Viiv Healthcare Uk (No. 5) Limited Inhibitors of human immunodeficiency virus replication

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020018459A1 (en) * 2018-07-16 2020-01-23 Gilead Sciences, Inc. Capsid inhibitors for the treatment of hiv
WO2020084492A1 (en) * 2018-10-24 2020-04-30 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
WO2020254985A1 (en) * 2019-06-19 2020-12-24 VIIV Healthcare UK (No.5) Limited Pyrido[2,3-d]pyrimidine derivatives as inhibitors of human immunodeficiency virus replication
WO2021209900A1 (en) * 2020-04-15 2021-10-21 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230011471A (ko) * 2016-08-19 2023-01-20 길리애드 사이언시즈, 인코포레이티드 Hiv 바이러스 감염의 예방적 또는 치유적 치료에 유용한 치료 화합물
TWI687415B (zh) * 2017-08-17 2020-03-11 美商基利科學股份有限公司 Hiv蛋白質膜抑制劑之固體形式

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020018459A1 (en) * 2018-07-16 2020-01-23 Gilead Sciences, Inc. Capsid inhibitors for the treatment of hiv
WO2020084492A1 (en) * 2018-10-24 2020-04-30 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
WO2020254985A1 (en) * 2019-06-19 2020-12-24 VIIV Healthcare UK (No.5) Limited Pyrido[2,3-d]pyrimidine derivatives as inhibitors of human immunodeficiency virus replication
WO2021209900A1 (en) * 2020-04-15 2021-10-21 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
STRICKLEY R G: "SOLUBILIZING EXCIPIENTS IN ORAL AND INJECTABLE FORMULATIONS", PHARMACEUTICAL RESEARCH, SPRINGER US, NEW YORK, vol. 21, no. 2, 1 February 2004 (2004-02-01), pages 201 - 230 *

Also Published As

Publication number Publication date
EP4415685A1 (en) 2024-08-21
IL311982A (en) 2024-06-01
CL2024001073A1 (es) 2024-10-04
KR20240074850A (ko) 2024-05-28
CA3234219A1 (en) 2023-04-20
AU2022362855A1 (en) 2024-05-02
MX2024004551A (es) 2024-06-26
JP2024535596A (ja) 2024-09-30
US20240423985A1 (en) 2024-12-26
WO2023062559A1 (en) 2023-04-20

Similar Documents

Publication Publication Date Title
TWI814350B (zh) 用於治療hiv之蛋白殼抑制劑
AU2021206907B2 (en) Solid forms of an HIV capsid inhibitor
TWI305527B (en) Synthesis of 4-(amino)-2-butenoyl chlorides and their use in the preparation of 3-cyano quinolines
AU2022362855B2 (en) Inhibitors of human immunodeficiency virus replication
AU717913B2 (en) Xanthines and their therapeutic use
EP1045690B1 (en) Benzenesulfonamide inhibitors of pde-iv and their therapeutic use
EP3266782B1 (en) Fluorinated integrin antagonists
TW202115055A (zh) 人類免疫缺乏病毒複製之抑制劑
US9650346B2 (en) Solid forms of antiretroviral compounds, process for the preparation and their pharmaceutical composition thereof
JP2014510139A (ja) 固体形態のｈｉｖ阻害剤
JP2016507489A (ja) 活性成分としてテトラゾール誘導体を含む、溶解性が改善された固体分散体
WO2020135401A1 (zh) 吡咯并嘧啶化合物的治疗用途及其固体药物组合物
JP7336017B2 (ja) ホウ素含有ｒｈｏキナーゼ阻害剤
CN118119376A (zh) 人类免疫缺陷病毒复制的抑制剂
AU2017211118A1 (en) Crystalline form of 1 ,3-thiazol-5-ylmethyl [(2R,5R)-5-{[(2S)-2-[(methyl{[2-(propan-2-yl)-1 ,3-thiazol-4-yl]methyl}carbamoyl)amino] -4-(morpholin-4-yl)butanoyl 9amino}-1 ,6-diphenylhexan-2-yl]carbamate or cobicistat
JP4875205B2 (ja) チアジアゾール誘導体の安定な製剤
HUP0300429A2 (hu) Javított felszívódási képességű szilárd diszperzió és eljárás az előállítására
TWI922180B (zh) 用於治療hiv之蛋白殼抑制劑
TW202602461A (zh) 抗ｈｉｖ化合物
HK40040234A (en) Capsid inhibitors for the treatment of hiv
BR122024007306A2 (pt) Composição farmacêutica que compreende o composto da fórmula ia, fórmula ib, fórmula ic ou fórmula id e uso da mesma para tratamento de infecção por hiv
JP2020515607A (ja) プロドラッグ組成物
HK1217696B (en) Fluorinated integrin antagonists

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)